New Research Reveals Hidden DNA Changes in Alzheimer's
Researchers have identified structural disruptions in the genome that may drive Alzheimer's disease beyond known protein markers.
A new study suggests that Alzheimer's disease involves more than just the buildup of toxic proteins. Scientists discovered that the three-dimensional folding of DNA is altered in specific brain cells of patients. This structural shift changes how genes are turned on or off, revealing a previously overlooked layer of the disease's biology.
The findings, reported by ScienceDaily, indicate that these genetic changes are not just random noise but are linked to the overall organization of brain tissue. While amyloid plaques and tau tangles remain the classic hallmarks of the condition, this research points to chromatin alterations as a distinct and significant component of the molecular pathology.
Genome structure shifts in brain cells
DNA inside a cell does not exist as a straight line; it folds into a complex three-dimensional shape. This physical arrangement acts as a regulatory mechanism, determining which genes are accessible and active. When this folding is disrupted, it can fundamentally alter how brain cells function. The research team found that in the prefrontal cortex, the genome organization in people with Alzheimer's differs significantly from those without the disease.
Combining advanced imaging and AI models
To map these changes, researchers used a technique called GAGE-seq, which measures both gene expression and genome contacts within single cells. They combined this with spatial transcriptomic maps to see exactly where these molecular changes occur within the brain tissue. To make sense of this massive dataset, the team developed an artificial intelligence model named Hicformer. This tool connects the physical folding of the genome to its regulatory effects, allowing scientists to see the bigger picture of how disease mechanisms fit together.
Moving beyond traditional disease markers
For decades, the focus on Alzheimer's has been on amyloid-beta plaques and tau tangles. While these remain important, the new findings suggest that higher-order chromatin alterations are also a core part of the disease. This means that treatments targeting only protein accumulation may be insufficient. By understanding how DNA structure influences gene activity, researchers can identify new mechanisms to test. This approach offers a more comprehensive view of the disease, potentially opening new avenues for effective therapies for the millions of people affected.
